Standout Papers

Efficacy of azacitidine compared with that of conventional care ... 2001 2026 2009 2017 1.7k
  1. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (2009)
    Pierre Fenaux, Ghulam J. Mufti et al. The Lancet Oncology
  2. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL (2018)
    Michael Hallek, Bruce D. Cheson et al. Blood
  3. Relation of Gene Expression Phenotype to Immunoglobulin Mutation Genotype in B Cell Chronic Lymphocytic Leukemia (2001)
    Andreas Rosenwald, Ash A. Alizadeh et al. The Journal of Experimental Medicine
  4. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody (2010)
    Don M. Benson, Courtney E. Bakan et al. Blood
  5. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 (2011)
    Sarah E. M. Herman, Amber Gordon et al. Blood
  6. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability (2010)
    Brian J. Lannutti, Sarah Meadows et al. Blood
  7. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. (1998)
    Clara D. Bloomfield, David Lawrence et al. PubMed
  8. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib (2015)
    John C. Byrd, Richard R. Furman et al. Blood
  9. Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor–Modified T Cells After Failure of Ibrutinib (2017)
    Cameron J. Turtle, Kevin A. Hay et al. Journal of Clinical Oncology
  10. Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma (2019)
    Talha Munir, Jennifer R. Brown et al. American Journal of Hematology
  11. Targeting the C481S Ibrutinib-Resistance Mutation in Bruton’s Tyrosine Kinase Using PROTAC-Mediated Degradation (2018)
    Alexandru D. Buhimschi, Momar Toure et al. Biochemistry
  12. Ibrutinib treatment improves T cell number and function in CLL patients (2017)
    Meixiao Long, Kyle A. Beckwith et al. Journal of Clinical Investigation

Immediate Impact

11 by Nobel laureates 6 from Science/Nature 88 standout
Sub-graph 1 of 19

Citing Papers

Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic Leukemia
2025 Standout
Diagnosis and Treatment of Chronic Lymphocytic Leukemia
2023 Standout
15 intermediate papers

Works of John C. Byrd being referenced

Acalabrutinib monotherapy in patients with chronic lymphocytic leukemia who are intolerant to ibrutinib
2019
Final analysis from RESONATE: Up to six years of follow‐up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
2019 Standout
and 29 more

Author Peers

Author Last Decade Papers Cites
John C. Byrd 14705 10360 9055 9156 696 27.4k
William G. Wierda 17768 12673 10760 8334 821 30.9k
Jan A. Burger 12612 8272 5971 5340 427 20.5k
Daniel Catovsky 19063 13429 14409 7116 530 34.7k
John G. Gribben 9015 8634 4954 4828 471 23.5k
Stephan Stilgenbauer 15835 12696 3415 6079 511 22.9k
Tadeusz Robak 9615 7531 5583 5216 688 18.7k
Thomas J. Kipps 19283 12970 4897 11521 616 34.4k
Alessandro Rambaldi 8352 4575 9429 7976 651 23.8k
Wolfgang Hiddemann 6722 9636 10804 7956 641 26.7k
Thomas E. Witzig 8428 13812 9376 10973 770 33.3k

All Works

Loading papers...

Rankless by CCL
2026